CEOCFO-Press Release

Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas.
Press Release - Proteonomix Inc. (PROT-OTC: BB)
	I believe that most investors should be aware of the synergy that exists between our subsidiaries. For example, our R&D in our subsidiary National Stem Cell Inc., utilized material from our other subsidiary SBNY to develop products for our Proteoderm subsidiary. What we would like to express to potential investors is the fact that when you invest in Proteonomix you really invest in several companies that are leading the way into the age of cellular medicine... - Michael Cohen (PROT) (Interview published August 22, 2010)
The Most Powerful Name In Corporate News and Information.
CURRENT ISSUE \| COVER ARCHIVES \| INDEX \| CONTACT \| FINANCIALS \| MARKETING SERVICES \| HOME PAGE

CEOCFO- Members Login Become A Member!	Proteonomix, Inc. (PROT) Announces the Formation of New Subsidiary, THOR BioPharma, Inc., to Provide an Entry Into the Pharmaceutical Market Proteonomix IncPROT \| 3/3/2011 9:02:02 AM MOUNTAINSIDE, NJ, Mar 03, 2011 (MARKETWIRE via COMTEX News Network) -- PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has formed a new subsidiary called THOR BioPharma, Inc., a Nevada Corporation. THOR BioPharma has been established with the intention to initialize the entry of Proteonomix into the Bio Pharmaceutical market. Proteonomix plans on utilizing THOR BioPharma Inc. to serve as a platform for technology it will seek to license that focuses on pharmaceutical products. THOR Biopharma's mission is to develop therapeutic biological agents capable of enhancing stem cell therapies to provide lifesaving clinical treatment of patients with debilitating diseases. THOR will focus initially on the licensing and development of therapeutic agents for critically ill patients. About Proteonomix, Inc.: Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix Family of companies includes Proteoderm, StromaCel, National Stem Cell, PRTMI, The Sperm Bank of New York and THOR Biopharma. Proteoderm, Inc. is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel, Inc. develops therapeutic modalities for the treatment of Cardiovascular Disease (CVD). National Stem Cell, Inc. is Proteonomix's operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/. Forward-looking statements: Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made. Contact: Proteonomix, Inc. Michael Cohen CEO Phone: +1-973-544-6116 Email: Email Contact SOURCE: Proteonomix http://www2.marketwire.com/mw/emailprcntct?id=B6227B7845E49864 Copyright 2011 Marketwire, Inc., All rights reserved.

ceocfointerviews.com does not purchase or make
recommendation on stocks based on the interviews published.